CoChat

Inclisiran in lipid management: A Literature overview and future perspectives

Open access
Scicchitano, Pietro, Milo, Michele, Mallamaci, Rosanna, De Palo, Micaela, Caldarola, Pasquale, Massari, Francesco, Gabrielli, Domenico, Colivicchi, Furio, Ciccone, Marco Matteo · 2021 · Biomedicine & Pharmacotherapy
Cited by 44

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Primary and secondary prevention protocols aim at reducing the plasma levels of lipids - with particular reference to low-density lipoprotein cholesterol (LDL-C) plasma concentrations - in order to improve the overall survival and reduce the occurrence of major adverse cardiovascular events. The use of statins has been widely considered as the first-line approach in lipids management as they can dramatically impact on the cardiovascular risk profile of individuals. The introduction of ezetimibe and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors overcame the adverse effects of statins and ameliorate the achievement of the target lipids levels. Indeed, advances in therapies promote the use of specific molecules - i.e. short strands of RNA named small-interfering RNAs (siRNAs) - to suppress the transcription of genes related to lipids metabolism. Recently, the inclisiran has been developed: this is a siRNA able to block the mRNA of the PCSK9 gene. About 50% reduction in low-density lipoprotein cholesterol levels have been observed in randomized controlled trials with inclisiran. The aim of this review was to summarize the literature regarding inclisiran and its possible role in the general management of patients with lipid disorders and/or in primary/secondary prevention protocols.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopha.2021.112227

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 44

Metadata

Authors
Scicchitano, P., Milo, M., Mallamaci, R., De Palo, M., Caldarola, P., Massari, F., Gabrielli, D., Colivicchi, F., & Ciccone, M. M.
Venue
Biomedicine & Pharmacotherapy
Publisher
Elsevier BV
Published
2021-11
Volume
143
Pages
112227
ISSN
0753-3322 (ISSN-L)
OpenAlex
W3202828330
Cited by
44
References
26
FWCI
7.41
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inclisiran in lipid management: A Literature overview and future perspectives. https://app.cochat.ai/papers/10.1016/j.biopha.2021.112227
The paper
Scicchitano, P., Milo, M., Mallamaci, R., De Palo, M., Caldarola, P., Massari, F., Gabrielli, D., Colivicchi, F., & Ciccone, M. M. (2021). Inclisiran in lipid management: A Literature overview and future perspectives. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2021.112227

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.